Phase 1 study of sorafenib and hepatic arterial infusion chemotherapy with Miriplatin for advanced Hepatocellular carcinoma.
Phase 1
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000008782
- Lead Sponsor
- Division of Gastroenterology,Kurume university School of Medicine
- Brief Summary
10 patients were registrated this study, 27, Feb, 2014 Liver disfunction: 4patients ascites :2patients SD / PD : 3 / 7 patients MST : 7.3 months
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.Previous hepatic resection or RFA within 4 weeks. 2.Patients with active double cancers. 3.Patients with concurrent infections 4.Patients with hypersensitivity to Miliplatin and contrast medium of iodine. 5.Pregnant, lacting women or women with suspected pregnancy. 6.Inappropriate patients for this study judged by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complication
- Secondary Outcome Measures
Name Time Method Response evaluation , overall survival